Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|May 12, 2015
DIR Technologies Signs Agreement with Pfizer
Under the terms of the agreement, Pfizer will have access to DIR Technologies’ inspection and quality control solutions.
Advertisement
DIR Technologies, a provider of quality and process control solutions for pharmaceutical primary packaging, has entered into a five-year agreement with Pfizer. Under the terms of the agreement, Pfizer will have access to DIR Technologies’ inspection and quality control solutions. The agreement opens up opportunities for joint projects pertaining to both production and packaging processes.
Among the solutions involved in the agreement is DIR Technologies’ induction integrity verification system (I2VS), which was introduced more than a year ago. According to DIR Technologies, the system is the first in the global pharmaceuticals market to perform in-line inspection on 100% of induction sealed bottles at the speed of the machine throughput. The I2VS is a workflow solution and an inspection device. The source of any potential faulty seals is indicated in real time, yielding a high degree of process understanding and the ability for operators to not only help fix potential faulty seals immediately, but also prevent them from occurring in the first place. The I2VS enables a new level of quality assurance and process control.
DIR Technologies and Pfizer also will be working together on the development of a new inspection technology based on DIR’s advanced high-speed imaging capabilities. The new system is intended to perform 100% in-line inspection of tablets and capsules.
Source: DIR Technologies
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement